{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/proactively-recognizing-and-managing-trial-risks-xcellerater-central-monitoring#webpage",
"url": "https://www.fortrea.com/insights/proactively-recognizing-and-managing-trial-risks-xcellerater-central-monitoring",
"name": "Proactively recognizing and managing trial risks with Xcellerate® Central Monitoring",
"description": "This Fortrea case study demonstrates how Xcellerate® Central Monitoring (XCM) supported clinical trial risk management through centralized monitoring, advanced analytics, and proactive risk identification. During a Phase IIa oncology study, XCM identified site-level anomalies related to adverse event (AE) and serious adverse event (SAE) reporting by analyzing data across study sites and highlighting reporting patterns that differed from expected trends. Traditional monitoring approaches may not have detected these issues early enough to prevent downstream impacts on study quality and compliance. Using near real-time analytics, cross-site comparisons, and centralized data review, XCM enabled study teams to investigate reporting inconsistencies, assess potential risks, improve data integrity, and implement corrective actions. The case study highlights how centralized monitoring and risk-based monitoring strategies can enhance risk identification, strengthen data quality, support compliance objectives, and improve oversight of critical clinical trial data through timely and actionable insights."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Proactively recognizing and managing trial risks with Xcellerate® Central Monitoring",
"item": "https://www.fortrea.com/insights/proactively-recognizing-and-managing-trial-risks-xcellerater-central-monitoring"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/proactively-recognizing-and-managing-trial-risks-xcellerater-central-monitoring#casestudy",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/proactively-recognizing-and-managing-trial-risks-xcellerater-central-monitoring#webpage"
},
"headline": "Clinical Trial Risk Management: Risk Identification and Mitigation with Xcellerate® Central Monitoring | Fortrea Case Study",
"description": "This Fortrea case study demonstrates how Xcellerate® Central Monitoring (XCM) supported clinical trial risk management through centralized monitoring, advanced analytics, and proactive risk identification. During a Phase IIa oncology study, XCM identified site-level anomalies related to adverse event (AE) and serious adverse event (SAE) reporting by analyzing data across study sites and highlighting reporting patterns that differed from expected trends. Traditional monitoring approaches may not have detected these issues early enough to prevent downstream impacts on study quality and compliance. Using near real-time analytics, cross-site comparisons, and centralized data review, XCM enabled study teams to investigate reporting inconsistencies, assess potential risks, improve data integrity, and implement corrective actions. The case study highlights how centralized monitoring and risk-based monitoring strategies can enhance risk identification, strengthen data quality, support compliance objectives, and improve oversight of critical clinical trial data through timely and actionable insights.",
"genre": "Case Study",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2026-04/xcellerate-risk-management.jpg"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2026-04-06",
"dateModified": "2026-04-06",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2026-04/xcellerate-trial-risk-management.pdf",
"encodingFormat": "application/pdf"
}
}
]
}